Wednesday, May 31, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

Antibiotics Update: Three Discovery Projects That You Should Know About

by Global Biodefense Staff
July 12, 2017

Superbugs & Superdrugs 2017Supported by BARDA, CARB-X and big pharma, Superbugs & Superdrugs USA will provide insight into both traditional and non-traditional approaches towards combatting AMR whilst looking at financing initiatives and keeping attendees at the forefront of clinical breakthroughs.

Understanding the translational link between animals and humans; navigating the pitfalls of early drug discovery; and evaluating the potential of immunotherapies will be a major focus, as will hearing from a selection of biotech and pharma companies currently undertaking clinical research. This will include case studies from Pfizer, MedImmune, Merck, Visterra and ContraFect.

Event highlights will include a keynote presentation by Tim Opperman, Senior Research Scientist from Microbiotix.

The talk will discuss advances in the three-prong approach taken by Microbiotix to address the problem of MDR Gram-negative pathogens. It is claimed that all three discovery projects have demonstrated efficacy in murine models of infection.

Project 1 Virulance -Funded by CARB-X: Attendees will hear how a novel phenoxyacetamide series exhibits potent activity against type 3 secretion in Pseudomonas aeruginosa by targeting the assembled needle protein PscF.

Project 2 Intrinsic Resistance: Microbiotix will explain how novel pyranopyridine inhibitors of RND-type efflux pump inhibitors exhibit broad spectrum activity against pathogens of the Enterobacteriaceae and favourable pharmacokinetics in mice.

Project 3 Novel Essential Target: The talk will explore how a series of novel oxadiazoles bind to a unique site on the ribosome, resulting in potent inhibition of the essential non-stop ribosome rescue pathway in Gram-positive and negative pathogens, including MDR Neisseria gonorrhoeae and Francisella tularensis. These compounds exhibited potent antibacterial activity and oral bioavailability.

A full speaker line-up and detailed agenda is available at www.superbugs-usa.com/globalbiodefence

Superbugs & Superdrug’s USA will take place on 13th and 14th November at the Renaissance Woodbridge Hotel in Iselin, New Jersey.

Tags: AntimicrobialsASPREventsHHS

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance
Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC